This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drug Development Advisory Firm Rosa & Co. LLC To Present Two Mechanistic Modeling Presentations At The 28th JSSX Conference

SAN CARLOS, Calif., Oct. 4, 2013 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that Dr. Mike Reed, Chief Scientist, and Dr. Christina Friedrich, Chief Engineer, will present at the Japanese Society for the Study of Xenobiotics, JSSX Annual Meeting ( October 9 th – 11 th), Tokyo, Japan. Dr. Reed's talk, entitled "Application of Mechanistic Physiological Modeling in the Drug Development Process – Overview and Case Studies", will introduce key features of mechanistic physiological models (also known as quantitative systems pharmacology or PhysioPD™ models), which are deployed in Rosa's practice. Dr. Reed will use multiple case studies to illustrate the application and impact of mechanistic models in drug discovery and development. Dr. Friedrich's seminar, entitled "Introduction of a Model Qualification Method (MQM) to foster model-based drug development in the exploratory phase of R&D" will outline the procedures and key qualification criteria of Rosa's MQM. Dr. Friedrich will describe the motivation behind each criterion and its role in confirming that a model is fit for purpose; examples will illustrate how the MQM approach ensures a successful modeling project.

(Logo: )

"We are honored to have the opportunity to speak at this very prestigious meeting," said Dr. Ron Beaver, Rosa's President and CEO.

About Rosa

Rosa helps clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these capabilities, Rosa's clients participate in customized model creation, testing, and research simulations, retain the models, and acquire the ability to perform model research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas. The Rosa team is unique in its breadth and depth of disease area experience, including metabolic diseases, oncology, inflammation, immune dysfunction, CNS, dermatology, and antibacterial/antiviral biology. For more information, visit

Press Contact: Rebecca Baillie 530-661-7476

Read more news from Rosa & Co. LLC


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs